Evaluation of the immunogenicity of replication-competent V-knocked-out and replication-defective F-deleted Sendai virus vector-based vaccines in macaques

Vaccine

Volumn 26, Issue 52, 2008, Pages 6839-6843

  Takeda, Akiko ^a   Igarashi, Hiroko ^b   Kawada, Miki ^a   Tsukamoto, Tetsuo ^a   Yamamoto, Hiroyuki ^a   Inoue, Makoto ^c   Iida, Akihiro ^c   Shu, Tsugumine ^c   Hasegawa, Mamoru ^c   Matano, Tetsuro ^a,d,e  

^a UNIVERSITY OF TOKYO   (Japan)

^b UNIVERSITY OF TOKYO   (Japan)

^c University of Tokyo   (Japan)

^d NATIONAL INSTITUTE OF INFECTIOUS DISEASES   (Japan)

^e NATIONAL INSTITUTE OF BIOMEDICAL INNOVATION   (Japan)

Author keywords

AIDS vaccine; Sendai virus vector; T cell response

Indexed keywords

DNA VACCINE; VIRUS VACCINE; VIRUS VECTOR;

ANIMAL EXPERIMENT; ARTICLE; DNA IMMUNIZATION; GENE DELETION; IMMUNOGENICITY; KNOCKOUT GENE; MACACA; NONHUMAN; PRIORITY JOURNAL; SENDAI VIRUS; T LYMPHOCYTE; VIRUS GENE; VIRUS REPLICATION;

ADMINISTRATION, INTRANASAL; ANIMALS; GENE PRODUCTS, GAG; GENETIC VECTORS; IMMUNITY, CELLULAR; LYMPH NODES; MACACA FASCICULARIS; MACACA MULATTA; NASAL MUCOSA; ORGANISMS, GENETICALLY MODIFIED; SENDAI VIRUS; T-LYMPHOCYTES; VACCINES, ATTENUATED; VACCINES, SYNTHETIC; VIRUS REPLICATION;

EID: 56649089688     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2008.09.074     Document Type: Article

References (22)

1. Koup R.A., Safrit J.T., Cao Y., Andrews C.A., Mcleod G., Borkowsky W., et al. Temporal association of cellular immune responses with the initial control of viremia in primary human immunodeficiency virus type 1 syndrome. J Virol 68 (1994) 4650-4655
2. + cytotoxic T-lymphocyte activity associated with control of viremia in primary human immunodeficiency virus type 1 infection. J Virol 68 (1994) 6103-6110
3. + T cell responses associated with control of viremia. Science 278 (1997) 1447-1450
4. Matano T., Shibata R., Siemon C., Connors M., Lane H.C., and Martin M.A. Administration of an anti-CD8 monoclonal antibody interferes with the clearance of chimeric simian/human immunodeficiency virus during primary infections of rhesus macaques. J Virol 72 (1998) 164-169
5. Brander C., and Walker B.D. T lymphocyte responses in HIV-1 infection: implication for vaccine development. Curr Opin Immunol 11 (1999) 451-459
6. Jin X., Bauer D.E., Tuttleton S.E., Lewin S., Gettie A., Blanchard J., et al. Dramatic rise in plasma viremia after CD8+ T cell depletion in simian immunodeficiency virus-infected macaques. J Exp Med 189 (1999) 991-998
7. Schmitz J.E., Kuroda M.J., Santra S., Sasseville V.G., Simon M.A., Lifton M.A., et al. Control of viremia in simian immunodeficiency virus infection by CD8+ lymphocytes. Science 28 (1999) 857-860
8. McMichael A.J., and Hanke T. HIV vaccines 1983-2003. Nat Med 9 (2003) 874-880
9. Matano T., Kano M., Nakamura H., Takeda A., and Nagai Y. Rapid appearance of secondary immune responses and protection from acute CD4 depletion after a highly pathogenic immunodeficiency virus challenge in macaques vaccinated with a DNA-prime/Sendai viral vector-boost regimen. J Virol 75 (2001) 11891-11896
10. Kano M., Matano T., Kato A., Nakamura H., Takeda A., Suzaki Y., et al. Primary replication of a recombinant Sendai viral vector in macaques. J Gen Virol 83 (2002) 1377-1386
11. Matano T., Kobayashi M., Igarashi H., Takeda A., Nakamura H., Kano M., et al. Cytotoxic T lymphocyte-based control of simian immunodeficiency virus replication in a preclinical AIDS vaccine trial. J Exp Med 199 (2004) 1709-1718
12. Nagai Y. Paramyxovirus replication and pathogenesis. Reverse genetics transforms understanding. Rev Med Virol 9 (1999) 83-99
13. Slobod K.S., Shenep J.L., Lujan-Zilbermann J., Allison K., Brown B., Scroggs R.A., et al. Safety and immunogenicity of intranasal murine parainfluenza virus type 1 (Sendai virus) in healthy human adults. Vaccine 22 (2004) 3182-3186
14. Kato A., Sakai Y., Shioda T., Kondo T., Nakanishi M., and Nagai Y. Initiation of Sendai virus multiplication from transfected cDNA or RNA with negative or positive sense. Genes Cells 1 (1996) 569-579
15. Kato A., Kiyotani K., Sakai Y., Yoshida T., and Nagai Y. The paramyxovirus, Sendai virus, V protein encodes a luxury function required for viral pathogenesis. EMBO J 16 (1997) 578-587
16. Kano M., Matano T., Nakamura H., Takeda A., Kato A., Ariyoshi K., et al. Elicitation of protective immunity against simian immunodeficiency virus infection by a recombinant Sendai virus expressing the Gag protein. AIDS 14 (2000) 1281-1282
17. Li H.O., Zhu Y.F., Asakawa M., Kuma H., Hirata T., Ueda Y., et al. A cytoplasmic RNA vector derived from nontransmissible Sendai virus with efficient gene transfer and expression. J Virol 74 (2000) 6564-6569
18. Takeda A., Igarashi H., Nakamura H., Kano M., Iida A., Hirata T., et al. Protective efficacy of an AIDS vaccine, a single DNA-prime followed by a single booster with a recombinant replication-defective Sendai virus vector, in a macaque AIDS model. J Virol 77 (2003) 9710-9715
19. Kiyotani K., Sakaguchi T., Kato A., Nagai Y., and Yoshida T. Paramyxovirus Sendai virus V protein counteracts innate virus clearance through IRF-3 activation, but not via interferon, in mice. Virology 359 (2007) 82-91
20. Shibata R., Maldarelli F., Siemon C., Matano T., Parta M., Miller G., et al. Infection and pathogenicity of chimeric simian-human immunodeficiency viruses in macaques: determinants of high virus loads and CD4 cell killing. J Infect Dis 176 (1997) 362-373
21. Kato M., Igarashi H., Takeda A., Sasaki Y., Nakamura H., Kano M., et al. Induction of Gag-specific T-cell responses by therapeutic immunization with a Gag-expressing Sendai virus vector in macaques chronically infected with simian-human immunodeficiency virus. Vaccine 23 (2005) 3166-3173
22. Suen J.Y., and Stern S.J. Cancer of the neck. In: Myers E.N., and Suen J.Y. (Eds). Cancer of the head and neck. 3rd ed. (1996), WB Saunders, Philadelphia 462-484